TACE after surgery for high-risk liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your liver cancer, and the cancer was confirmed as hepatocellular carcinoma (HCC).
- You are generally active and able to do light work (ECOG score 0 or 1).
- Your liver function is good (Child-Pugh class A or B7).
- You have at least one high-risk factor for the cancer coming back (e.g., tumor >5 cm, multiple tumors, or blood vessel invasion).
- You have not had any previous cancer treatment for your liver cancer before this surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a procedure called TACE (which blocks the blood supply to the tumor) with surgery to remove a large liver tumor. It is for people newly diagnosed with a large liver cancer that hasn't spread and can be completely removed with surgery.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
This trial tests a combination of treatments for liver cancer that can be surgically removed. It adds immunotherapy drugs (Iparomlimab and Tuvonralimab, together called QL1706) and targeted therapy (Lenvatinib) to a procedure called TACE (chemoembolization) to see if this approach shrinks the tumor and lowers the chance of recurrence after surgery.
This trial studies a treatment approach (a combination given through the liver) for people with early liver cancer that can be surgically removed but has a high chance of coming back. It may help reduce the risk of recurrence after treatment.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.